Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07576530

HOLA Intervention Pilot

The patient-clinician relationship is fundamental to providing high-quality patient-centered medical care. A therapeutic alliance (TA) is a patient clinician relationship that is characterized by mutual caring, trust, understanding, and respect. A strong TA between oncologists and patients with advanced cancer is associated with several positive health outcomes for patients and caregivers. However, previous work showed a stark disparity in the TA for Latino/a patients with advanced cancer vs. non-Latino/a white patients. The overall objective of this study is to pilot the Heightening Oncologist-Latino/a cancer patient Alliances (HOLA) intervention to assess its feasibility, acceptability, and appropriateness, and the preliminary efficacy of the intervention's impact on the TA between oncologists and their Latino/a patients with advanced cancer. The HOLA intervention will teach oncologists specific evidence based skills and behaviors for promoting a TA with Latino/a advanced cancer patients through the integration of patient-centered communication techniques that are aligned with Latino/a cultural values via commonly encountered clinical scenarios. The investigators will pilot test the HOLA intervention with eight oncologists and 32 of their patients, half (n=16 patients) who are under the care of an oncologist who will be randomized to receive the TA intervention (n=4 oncologists), and half (n=16 patients) who are under the care of an oncologist (n=4 oncologists) who was randomized to usual care. The feasibility, acceptability, and appropriateness of the intervention will be assessed using standard measures. Preliminary efficacy will be determined by comparing the mean TA scores for the oncologists who were randomized to receive the intervention to the mean TA scores for the oncologists who were randomized to usual care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • identifying as ethnically Latino;
  • locally advanced or metastatic cancer (pancreaticobiliary, esophagogastric, hepatocellular carcinoma, lung, or gynecological cancer) AND have experienced disease progression on at least first-line chemotherapy
  • ability to provide informed consent.

Exclusion criteria

  • not fluent in English or Spanish;
  • severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of < 6 during screening);
  • too ill or weak to complete the interviews (as judged by interviewer);
  • children and young adults under age 21
  • patients deemed inappropriate for the study by their treating oncologist.

Treatment and study plan

HOLA Intervention

Other

The HOLA intervention is aimed at oncologists and consists of a one hour interactive didactic session and a one-hour small group session.

Pre-recorded video vignettes and role playing with a trained moderator will be incorporated both into the interactive group didactic session and the small group session.

Primary outcomes

  1. Feasibility of Intervention

    Time frame: From enrollment to the end of intervention at 1 to 3 months

    Will be assessed using the Feasibility of Intervention

    Measure, which consists of 4 questions:

    • [Intervention] seems implementable.
    • [Intervention] seems possible.
    • [Intervention] seems doable.
    • [Intervention] seems easy to use. Responses are on a 5-point Likert Scale, ranging from completely agree to completely disagree.
  2. Accessibility

    Time frame: From enrollment to the end of intervention at 1 to 3 months

    Will be assessed using the Acceptability of Intervention

    Measure, which consists of 4 questions:

    • [Intervention] meets my approval, 2) [Intervention] is appealing to me, 3) I like [Intervention], 4) I welcome [Intervention]. Responses are on 3 5-point Likert Scale, ranging from completely agree to completely disagree.
  3. Appropriateness of Intervention

    Time frame: From enrollment to the end of the intervention at 1 to 3 months

    Will be assessed using the Intervention

    Appropriateness Measure, which consists of 4 questions:

    • [Intervention] seems fitting, 2) [Intervention] seems suitable, 3) [Intervention] seems applicable, 4) [Intervention] seems like a good match. Responses are on a 5-point Likert Scale, ranging from completely agree to completely disagree.

Secondary outcomes

  1. Preliminary efficacy of the intervention

    Time frame: From enrollment to the end of the intervention at 1 to 3 months

    Preliminary efficacy of the intervention for improving the TA between oncologists and Latino advanced cancer patients will be assessed by comparing mean patient TA scores, as measured by The Human Connection Scale (HCS), which consists of 16 likert-scale questions regarding the patient's relationship to their oncologist. The minimum value of the scale is 16 and the maximum value is 64, with higher scores indicating a better outcome (stronger therapeutic alliance/human connection).

Sponsors and collaborators

Lead sponsor

Rutgers, The State University of New Jersey

Other

Registry information

Official study title

Heightening Oncologist-Latino/a Cancer Patient Alliances (HOLA) Intervention Pilot Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 8, 2026
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.